

American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

KENNETH G. SAAG,¹ GIM GEE TENG,¹ NIVEDITA M. PATKAR,¹ JEREMY ANUNTIYO,²
CATHERINE FINNEY,² JEFFREY R. CURTIS,¹ HAROLD E. PAULUS,² AMY MUDANO,¹ MARIA PISU,¹
MARY ELKINS-MELTON,¹ RYAN OUTMAN,¹ JEROAN J. ALLISON,¹ MARIA SUAREZ ALMAZOR,³
S. LOUIS BRIDGES, JR.,¹ W. WINN CHATHAM,¹ MARC HOCHBERG,⁴ CATHERINE MACLEAN,⁵
TED MIKULS,⁶ LARRY W. MORELAND,⁷ JAMES O'DELL,⁵ ANTHONY M. TURKIEWICZ,¹ AND
DANIEL E. FURST²

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.

Introduction

The majority of patients with a confirmed diagnosis of rheumatoid arthritis (RA) use nonbiologic disease-modify-

ing antirheumatic drugs (DMARDs) and the rate of biologic DMARD use is rising rapidly (1,2). The American College of Rheumatology (ACR) has not updated its recommenda-

Dr. Saag's work was supported by the Agency for Healthcare Research and Quality (grant U18-H510389), the University of Alabama, Birmingham Center for Education and Research on Therapeutics of Musculoskeletal Diseases, and a grant from the American College of Rheumatology. Drs. Pisu, Allison, and Moreland's work was supported by a grant from the American College of Rheumatology. Dr. Furst's work was supported by a grant from the American College of Rheumatology and the NIH.

¹Kenneth G. Saag, MD, MSc, Gim Gee Teng, MD, Nivedita M. Patkar, MD, MSPH, Jeffrey R. Curtis, MD, MPH, Amy Mudano, MPH (current address: Blue Cross and Blue Shield of Alabama, Birmingham), Maria Pisu, PhD, Mary Elkins-Melton, BA, Ryan Outman, MS, Jeroan J. Allison, MD, MS, S. Louis Bridges, Jr., MD, PhD, W. Winn Chatham, MD, Anthony M. Turkiewicz, MD: University of Alabama, Birmingham; ²Jeremy Anuntiyoy, MD, Catherine Finney, MD, Harold E. Paulus, MD, Daniel E. Furst, MD: University of California, Los Angeles; ³Maria Suarez Almazor, MD, MPH: University of Texas, MD Anderson, Houston; ⁴Marc Hochberg, MD, MPH: University of Maryland, Baltimore; ⁵Catherine MacLean, MD, PhD, James O'Dell, MD: University of California, Los Angeles, RAND Corporation, Santa Monica, and West Los Angeles VAMC; ⁶Ted Mikuls, MD, MSPH:

University of Nebraska, Omaha; ⁷Larry W. Moreland, MD: University of Pittsburgh, Pittsburgh, Pennsylvania.

Dr. Saag has received consultant fees (less than \$10,000 each) from Roche, UCB, Nitec, and Amgen and research support from Abbott, Amgen, Centecor, Roche, and Wyeth. Dr. Curtis has received consultant fees, speaking fees, and/or honoraria (less than \$10,000 each) from Roche, Merck, Procter and Gamble, Eli Lilly, UCB, and Novartis and research support from Amgen, Eli Lilly, Merck, Novartis, Procter and Gamble, and Roche. Dr. Paulus has received consultant fees (less than \$10,000 each) from Amgen, Roche and Mathematica. Dr. Chatham has received speaking fees and honoraria (less than \$10,000 each) from Bristol-Myers Squibb and Amgen. Dr. Hochberg has received consultant fees (less than \$10,000 each) from Amgen and Bristol-Myers Squibb. Dr. MacLean owns stock and/or holds stock options in WellPoint. Dr. Mikuls has received speaking fees (less than \$10,000 each) from Genentech and Amgen and unrestricted grants from Abbott, Amgen, and Bristol-Myers Squibb. Dr. Moreland has received consultant fees, speaking fees, and/or honoraria (less than \$10,000 each) from Roche, Bristol-Myers Squibb, Centecor, Pfizer, Amgen, Incyte, and Genentech. Dr. O'Dell has received consultant fees and speaking fees (less than \$10,000) from Abbott. Dr. Turkiewicz has received consultant fees and speaking fees (less than \$10,000)

tions for nonbiologic DMARDs since 2002 (3) and has not previously developed recommendations for biologic agents. Although past guidelines have been derived from an informal consensus approach, we used a formal group process to develop recommendations that were as evidence-based as possible.

To develop these new recommendations on behalf of the ACR, following the principles delineated by the Appraisal of Guidelines for Research and Evaluation (AGREE) Col-

from Pfizer, honoraria (less than \$10,000 each) from Amgen, Wyeth, and Hoffman-LaRoche, and consultant fees, speaking fees, and honoraria (more than \$10,000) from Abbott. Dr. Furst has received consultant fees, speaking fees, and/or honoraria (less than \$10,000 each) from Abbott, Actelion, Amgen, Array, Biogenidec, Bristol-Myers Squibb, Centocor, Genentech, Gilead, GlaxoSmith-Kline, Encysive, Nitec, Novartis, Roche, TAP, UCB, Wyeth, and Xoma and research support from Actelion, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Novartis, Roche, and UCB.

Members of the Core Expert Panel: Kenneth G. Saag, MD, MSc, Jeffrey R. Curtis, MD, MPH, Harold E. Paulus, MD, Jeroan J. Allison, MD, MS, Maria Suarez Almazor, MD, MPH, S. Louis Bridges, Jr., MD, PhD, W. Winn Chatham, MD, Marc Hochberg, MD, MPH, Catherine MacLean, MD, PhD, Ted Mikuls, MD, MSPH, Larry W. Moreland, MD, James O'Dell, MD, Anthony M. Turkiewicz, MD, Daniel E. Furst, MD.

Members of the Task Force Panel: Claire Bombardier, MD, MSc (University of Toronto, Toronto, Ontario, Canada), Robin K. Dore, MD (University of California, Los Angeles), Linda F. Golodner, BA (National Consumers League, Washington, DC), Sean Hennessy, PharmD, PhD (University of Pennsylvania School of Medicine, Philadelphia), Arthur F. Kavanaugh, MD (University of California, San Diego), Dinesh Khanna, MD, MSC (University of Cincinnati, Cincinnati, Ohio, current address: University of California, Los Angeles), Joel M. Kremer, MD (Albany Medical Center, Albany, NY), Amye L. Leong, MBA (US Bone and Joint Decade, North Wales, PA), Eric L. Matteson, MD, MPH (Mayo Clinic, Rochester, MN), John T. Schousboe, MD, MS (Park Nicollet Clinic, St. Louis Park, MN, and University of Minnesota, Minneapolis), Anna N. A. Tosteson, ScD (Dartmouth Medical School, Lebanon, NH), Peter Tugwell, MD (University of Ottawa, Ottawa, Ontario, Canada), Yusuf Yazici, MD (New York University Hospital for Joint Diseases, New York).

Additional members of the University of Alabama, Birmingham (UAB) and University of California, Los Angeles (UCLA) Working Groups: Timothy Beukelman, MD, Maria I. Danila, MD, MS, Jeffrey Faggard, MD, Angelo Gaffo, MD, Allyson McDonough, MD, Raj Nair, MD, Bitu Shakoory, MD, Martha Verchot, MS, MLS (UAB), Paul Maranian, MS, Shruti Scott, MPH (UCLA).

Content Specific Expert Advisors: Kevin L. Winthrop, MD, MPH (tuberculosis; Oregon Health and Science University, Portland), Gregory J. Gores, MD (hepatology; Mayo Clinic, Rochester, MN), Michael Saag, MD (human immunodeficiency virus; University of Alabama, Birmingham), Paul Shekelle, MD, PhD (RAND/UCLA Appropriateness Method; University of California, Los Angeles).

The American College of Rheumatology is an independent, professional, medical, and scientific society, which does not guarantee, warrant, or endorse any commercial product or service.

Address correspondence to Daniel E. Furst, MD, University of California, Los Angeles Rehabilitation Institute, 1000 Veteran Avenue, Room 32-59, Los Angeles, CA 90025. E-mail: furst@mednet.ucla.edu.

Submitted for publication December 10, 2007; accepted in revised form March 13, 2008.




Figure 1. Methodologic process for the American College of Rheumatology recommendations for the use of biologic and nonbiologic disease-modifying antirheumatic drug therapies. RAND/UCLA = Research and Development/University of California at Los Angeles.

laboration (4), we first conducted a systematic review of scientific evidence to create an evidence report and draft guidelines. We addressed each of the 5 domains prespecified by the ACR, namely: 1) indications for use; 2) screening for tuberculosis (TB; biologic DMARDs only); 3) monitoring for side effects; 4) assessing the clinical response; and 5) the roles of cost and patient preferences in decision-making (biologic DMARDs only). A Working Group and a Core Expert Panel (CEP) of clinicians and methodologists guided the development of these recommendations. We next convened a Task Force Panel (TFP) of internationally-recognized clinicians, methodologists, and patient representatives with broad expertise in the use of nonbiologic and biologic DMARD therapies, evidence-based medicine, patient preference, and health care economics. They were to critique and rate proposed recommendations using a well-accepted group process, the modified Research and Development/University of California at Los Angeles (RAND/UCLA) Appropriateness Method (5) (Figure 1). Although the TFP and CEP considered drug-specific indications from the US Food and Drug Administration (FDA) and other regulatory authorities, in some cases the TFP extrapolated recommendations outside the present bounds of approved labeling. Although terminology used by regulatory agencies varies, in this article we refer to biologic agents as drugs.

Disseminated under the aegis of the ACR, we recognize that recommendations surrounding certain issues (e.g., cost considerations and TB testing approaches) may not be generalizable outside North America; however, we hope that these recommendations will have relevance to arthritis practitioners throughout the world.

To better reflect the underlying purpose of the endeavor, the output from this project is termed recommendations, rather than guidelines. These recommendations were developed for specialist clinicians familiar with assessing RA disease activity and disease severity. Applying these recommendations to clinical practice requires in-

dividualized patient assessment and clinical decision-making. The recommendations developed are not intended to be used in a “cookbook” or prescriptive manner or to limit a physician’s clinical judgment, but rather to provide guidance based on clinical evidence and expert panel input.

Methods for Development of ACR RA Recommendations

Systematic literature review: sources and databases.

Literature searches for both nonbiologic and biologic DMARDs relied predominantly on PubMed (from January 1, 1966 through January 31, 2007 and from January 1, 1998 through February 14, 2007, respectively). For biologic DMARDs, systematic searches were also conducted using EMBASE, SCOPUS, Web of Science, and the International Pharmaceutical Abstracts (IPA) computerized bibliographic databases (through June 20, 2006) by applying medical subject headings (MeSH) and relevant keywords (see Appendix A, available at the *Arthritis Care & Research* Web site at <http://www.interscience.wiley.com/jpages/0004-3591:1/suppmat/index.html>). For both nonbiologic and biologic DMARDs, we supplemented searches by checking references cited in published systematic reviews and by reference to the bibliographies of the articles extracted from the literature reviews. To ensure as complete a listing as possible of available important literature, the CEP and TFP identified additional studies.

Data from the FDA Adverse Event Reporting System and unpublished data from product manufacturers or investigators were not solicited or included in the systematic review unless they were identified by the literature search and met the inclusion criteria.

Literature search domains. Literature on the following nonbiologic DMARDs was examined: azathioprine, hydroxychloroquine, leflunomide, methotrexate, minocycline, organic gold compounds, sulfasalazine, and, when appropriate, combination therapy with methotrexate plus cyclosporine, methotrexate plus hydroxychloroquine, methotrexate plus leflunomide, methotrexate plus sulfasalazine, sulfasalazine plus hydroxychloroquine, and methotrexate plus hydroxychloroquine plus sulfasalazine. Additionally, the medical literature was examined for 6 biologic agents: etanercept, infliximab, adalimumab, anakinra, abatacept, and rituximab.

The 2 principles of our maximally inclusive search approach were to address indications and therapeutic response to nonbiologic DMARDs and biologic agents for RA, and to address the potential adverse events of nonbiologic and biologic DMARDs including TB for biologic DMARDs. Cost and patient preference were addressed for biologic DMARDs but not nonbiologic DMARDs, based on the specific ACR mandate for cost recommendations.

Subheadings, MeSH terms, and synonyms for the 6 biologic DMARDs and the 6 nonbiologic DMARDs (plus 5 nonbiologic DMARD combinations) were imputed as “substance names” and as “text words” that were applied to the medical databases. Details of the search strategy are listed in Appendix A (available at the *Arthritis Care & Research*

Web site at <http://www.interscience.wiley.com/jpages/0004-3591:1/suppmat/index.html>).

Literature search limits and article selection criteria.

Appropriate studies addressing the use of nonbiologic DMARDs and biologic agents were identified within each of the 5 domains that were specified by the ACR. Our literature search was limited to original research involving human subjects, published in English, and having abstracts. The search identified 3,878 citations for nonbiologic DMARDs and 6,818 citations of potential interest for biologic therapies (see Appendix B, available at the *Arthritis Care & Research* Web site at <http://www.interscience.wiley.com/jpages/0004-3591:1/suppmat/index.html>). Seven reviewers (3 for biologics, 4 for nonbiologics) screened each title and abstract for relevance to the domains.

Reviewers excluded articles based on abstract review if: 1) the report was a meeting abstract, case series, or case report with <30 patients or the study duration was <6 months; 2) nonbiologic DMARDs were used for non-RA conditions (e.g., psoriatic arthritis, systemic lupus erythematosus); 3) biologic DMARDs were used in health conditions not included in the FDA label (e.g., Wegener’s granulomatosis); or 4) biologic DMARDs were used in conditions not relevant to the ACR domains of interest (e.g., the use of rituximab in the treatment of lymphoma). Review articles and meta-analyses were excluded from our systematic reviews. However, meta-analyses were examined later to find other references, and they were referenced in supplementary qualitative reviews on selected adverse event domains (e.g., perioperative, vaccinations, pregnancy).

After exclusions based on abstract review, 801 full-text articles were retrieved and considered further for full review. This number included 515 articles that focused on nonbiologic DMARDs, 226 that focused on biologic DMARDs, and 60 that focused on cost. For nonbiologic DMARDs, a consensus of 2 reviewers determined articles not appropriate for full review. For biologic agents, the full text of all articles was reviewed by 2 independent reviewers by applying the same criteria as for nonbiologic DMARDs. If there was discordance on whether to include a study, it was resolved by a third reviewer. After additional exclusion of reviews, non-English language articles, nondomain topics, unapproved disease indications, lack of clinical outcomes of interest, non-FDA-approved regimens, study duration <6 months, and case series ($n < 30$), the final number of included articles for biologic agents was 125 (see Appendices B and C, available at the *Arthritis Care & Research* Web site at <http://www.interscience.wiley.com/jpages/0004-3591:1/suppmat/index.html>). Twenty-eight articles that also addressed cost factors associated with biologic agents were included. For nonbiologic DMARDs, the number of included articles was 142 (see Appendix B, available at the *Arthritis Care & Research* Web site at <http://www.interscience.wiley.com/jpages/0004-3591:1/suppmat/index.html>).

Each article about nonbiologic DMARDs was reviewed and key article elements entered into a database by 1 of 4 reviewers. A random 5% of the articles were re-reviewed

Table 1. Instruments used to measure rheumatoid arthritis disease activity*

Instrument (ref.)	Score range	Thresholds of disease activity		
		Low	Moderate	High
Disease Activity Score in 28 joints (253)	0–9.4	≤3.2	>3.2 and ≤5.1	>5.1
Simplified Disease Activity Index (103)	0.1–86.0	≤11	>11 and ≤26	>26
Clinical Disease Activity Index (103)	0–76.0	≤10	>10 and ≤22	>22
Rheumatoid Arthritis Disease Activity Index (254)	0–10	<2.2	≥2.2 and ≤4.9	>4.9†
PAS or PASII (14)	0–10	<1.9	≥1.9 and ≤5.3	>5.3
Routine Assessment Patient Index Data (255)	0–30	<6	≥6 and ≤12	>12

* Methods for calculating various instrument scores are shown in Appendix E (available at the *Arthritis Care & Research* Web site at <http://www.interscience.wiley.com/jpages/0004-3591:1/suppmat/index.html>). PAS = Patient Activity Scale.
† Median.

by one reviewer; concordance on this re-review was >80%. For biologic agents, the article review was performed by 1 reviewer and checked by a second reviewer. Discordance on the database entries was resolved by consensus between the 2 reviewers, and in the event of continuing disagreement, the opinion of a third reviewer was considered final. For each included article, study characteristics were summarized in tabular and graphic format, and a synthesis of the systematic literature review was developed into a comprehensive evidence report and used to craft clinical scenarios (described below and in Appendix D, available at the *Arthritis Care & Research* Web site at <http://www.interscience.wiley.com/jpages/0004-3591:1/suppmat/index.html>).

Quality assessment of articles included in the literature review. The quality of randomized controlled trials (RCTs) was assessed by 2 reviewers using the Jadad instrument (6). Higher scores on this 5-point scale indicate higher quality. Articles related to nonbiologic DMARDs had a median Jadad score of 3 (interquartile range [IQR] 2–4). For biologic DMARDs, articles reviewed for these recommendations had a median Jadad score of 5 (IQR 3–5), reflecting the more modern study designs for the biologic DMARDs.

For observational studies (case–control and cohort), we used the Newcastle-Ottawa Scale (NOS) (range 0–9) (7). Higher scores on this scale indicate higher quality. For nonbiologic DMARD articles reviewed, the median NOS score was 3 (IQR 2.25–3.75), while the median NOS score for the biologic DMARDs was 7 (IQR 5–8), reflecting the newer literature and study designs for the biologic DMARDs.

Defining important clinical factors necessary for therapeutic decision-making. *Modified Delphi process by the CEP to establish key parameters for decision scenarios.* After establishing a diagnosis of RA, risk assessment is crucial for guiding optimal treatment. We used a modified Delphi process (8) to reach consensus and enrich response categories on questions related to key clinical thresholds and decision branch points of RA treatment strategies. This included definitions of what constituted DMARD failure, definitions of poor prognosis, categories of potential contraindications to DMARD use, and reasons for discontinuation of DMARDs.

To apply results from research studies to clinical practice, the CEP recommended that RA disease duration, disease activity, and factors related to a poor prognosis in RA be explicitly defined and used to help formulate practical recommendations (see below).

RA disease duration. Based on RA disease duration intervals commonly used in published RA clinical trials, disease duration thresholds were chosen to help with clinical decision-making. There were 3 categories of disease duration: <6 months (considered to be equivalent to early disease), 6–24 months (considered to be equivalent to intermediate disease duration), and >24 months (considered to be long or longer disease duration). For biologic therapies, early disease was further subdivided by disease duration of ≤3 months or 3–6 months, when disease activity was high.

RA disease activity assessment. Several indices to measure RA disease activity have been developed, each of which has advantages and disadvantages (9–15). Recent composite and patient-reported disease activity measures, many of which do not require laboratory testing, are summarized in Table 1 and Appendix E (available at the *Arthritis Care & Research* Web site at <http://www.interscience.wiley.com/jpages/0004-3591:1/suppmat/index.html>). Evidence-based guidelines require clear definitions of disease activity to make rational therapeutic choices, but it is not possible or appropriate to mandate use of a single disease activity score for the individual physician, and different studies have used different definitions. Therefore, the TFP was asked to consider a combined estimation of disease activity, which allowed reference to many past definitions. With the instruments in Table 1 as a guide, we rated RA disease activity in an ordinal manner as low, moderate, or high, as previously requested by the CEP (Table 1). The TFP was then asked to make judgments based on these cut points.

Prognostic factors for RA. RA patients with features of a poor prognosis have active disease with high tender and swollen joint counts, often have evidence of radiographic erosions, elevated levels of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies (16–20), an elevated erythrocyte sedimentation rate, and/or an elevated C-reactive protein level (21,22). Older age, female sex, genotype (HLA-DRB1 shared epitope), worse physical functioning based on the Health Assess-

ment Questionnaire (HAQ) score, and cigarette smoking are also important predictors for a worse RA outcome, radiographic progression, early disability, and morbidity (such as increased risk of the need for joint replacement) (23–31). Through a modified Delphi process, the CEP selected the following as the most clinically important markers of poor prognosis: functional limitation (e.g., HAQ Disability Index), extraarticular disease (e.g., vasculitis, Sjögren's syndrome, RA lung disease, etc.), RF positivity and/or positive anti-CCP antibodies (both characterized dichotomously, per CEP recommendation), and/or bony erosions by radiography. For the purposes of selecting therapies, physicians should consider the presence of these prognostic factors at the time of the treatment decision. Although these prognostic factors are not exclusive, they are commonly used and have good face validity. Including combinations of these factors to guide decision-making would have added untenable complexity to a process that involved deliberate consideration of every permutation in a separate clinical scenario.

RAND/UCLA appropriateness method using the TFP.

The RAND/UCLA appropriateness process (32–34), which incorporates elements of the nominal and Delphi methods, was used to craft the final recommendations from clinical scenarios. These clinical scenarios, which described the potential key permutations of particular therapeutic considerations, were drafted by the investigators and CEP, based on the evidence report (Figure 1 and Appendix D, available at the *Arthritis Care & Research* Web site at <http://www.interscience.wiley.com/jpages/0004-3591:1/suppmat/index.html>). Via e-mail, the TFP received these clinical scenarios, instructions for grading scenarios, and definitions of all variables. Using a 9-point Likert scale, panelists were asked to use the evidence report and their clinical judgment to rate the appropriateness of various clinical scenarios pertaining to key clinical parameters (e.g., “In a patient who has had an inadequate response to a nonbiologic DMARD, has RA of 6 months duration, poor RA prognostic features, and moderate RA disease activity, would it be appropriate to add or switch to an anti-tumor necrosis factor α [anti-TNF α] agent?”). An initial set of scenario ratings occurred before each TFP meeting, and a second set of ratings occurred after discussion of the evidence at each TFP meeting. Disagreement regarding a specific scenario (e.g., disagreement with the initiation of combination therapy with methotrexate and hydroxychloroquine in mild early RA) was defined when one-third or more of the panelists rated a scenario in the lowest 3 points of the appropriateness scale (ordinal scores 1, 2, or 3) and one-third or more of the panelists rated the same scenario in the highest 3 points (ordinal scores 7, 8, or 9). In the absence of disagreement, a median rating in the lowest 3 points classified a scenario permutation as “inappropriate,” and a median rating in the upper 3 points classified a scenario as “appropriate.” Those scenario permutations rating in the 4–6 range together with those with disagreement were classified as “uncertain.”

The dispersion of the scores and ranges plus each individual's own score was shown to each panelist. The

median score provided the degree of agreement. In most circumstances, the recommendations for indications, contraindications, and safety monitoring for use of therapeutic agents include only positive statements. For example, it was agreed that methotrexate should be used in the setting of early RA without features of a poor prognosis. In contrast, there was no agreement regarding the use of rituximab in that circumstance, so no statement or recommendation was made. As another example, the TFP believed that hydroxychloroquine was not contraindicated for patients with acute serious bacterial infection. Since this was a negative statement (no contraindication), no recommendation was provided. For some particularly contentious areas (e.g., the use of biologic agents during pregnancy or the use of nonbiologic agents during the perioperative period), an absence of consensus is documented, and we directly state that no recommendation is provided. An absence of consensus and consequent lack of a positive statement should not be construed to indicate that the TFP did not consider these issues important, only that consensus was not reached, often due to absent or conflicting evidence. In these areas, therapeutic decisions are left to the careful consideration of risks/benefits by the patient and physician.

The anonymous ratings of the first round of ordinal voting were reviewed with the panelists at each meeting. The CEP were invited to participate during all the discussions with the TFP but were nonvoting participants. Through these discussions, the reasons for any uncertainty were identified, and resolution of discordance was attempted by modification of the clinical scenarios, clarification of definitions, or acknowledgment of discordance between clinical experience and the medical literature. In addition, the TFP identified important clinical situations that were not discussed during the face-to-face meeting or during the 4 subsequent Internet teleconferences. When identified and necessary, additional clinical questions were recommended by the panelists, formulated into decision scenarios, and evaluated using the same process. All clinical scenarios were subjected to at least 2 rounds of voting.

Conversion of clinical scenarios to ACR RA treatment recommendations. Following the second round of voting, recommendation statements were developed from a direct distillation of the scenario votes, and these statements were reviewed by the CEP. Although more than 2,000 clinical scenarios were graded by the TFP, there were very few areas of inconsistency or illogical results. When inconsistent or illogical findings were identified, the TFP was asked to reconsider and in some cases revote on these scenarios, using a new Delphi process.

Rating the strength of evidence for recommendations.

For each final recommendation, the strength of evidence was assigned using the methods of the American College of Cardiology (35) as follows: 1) for level of evidence A, data were derived from multiple RCTs or meta-analyses; 2) for level of evidence B, data were derived from a single

randomized trial or nonrandomized studies; 3) for level of evidence C, data were derived from consensus opinion of experts, case studies, or standards of care. In many circumstances, level C evidence denoted a circumstance in which medical literature (potentially including randomized trials, observational studies, or case series) might have addressed the general topic under discussion, but the literature did not address the specific clinical situations or scenarios reviewed by the TFP. For example, an RCT might have addressed only RF-positive patients, but the recommendation focused on patients without markers of a poor prognosis (i.e., those who were RF negative). This situation required a combination of judgment, extrapolation of the evidence, and group consensus. We have denoted this particular circumstance as level C* evidence.

In studies with more than 1 treatment arm, if each arm was efficacious when compared with baseline, the study was considered appropriate to support all DMARDs studied. The average disease duration of a study was considered when choosing appropriate reports for a duration category: <6 months, 6–24 months, and >24 months. Surrogates for poor prognosis (see above) were extracted and used when possible. For example, if >50% of patients in a nonbiologic DMARD arm were RF positive and the DMARD was shown to be efficacious, then the study was used to support a consensus statement for using that DMARD in RA patients who had a feature suggestive of a poor prognosis (Table 1).

ACR peer review of recommendations. Following construction of the recommendations, the ACR invited peer review by the ACR Guidelines Subcommittee members, ACR Quality of Care Committee members, and the ACR Board of Directors, and more than a dozen individuals from these groups responded with reviews and recommendations. In addition, ACR members were given an opportunity to provide feedback at a session at the 2007 Annual Scientific Meeting held in Boston, MA. The recommendations were ultimately subject to the regular journal review process.

Periodic re-review and updates of ACR recommendations. Although we used the most up-to-date literature available through February 2007 for our systematic review, rapid changes are occurring in evidence regarding nonbiologic and biologic therapeutics. Changing third-party coverage (e.g., through Medicare Part D) also may affect drug availability and patient preferences for therapies. These and other ongoing changes will inform decision-making about efficacious and safe use of biologic and nonbiologic DMARDs. In order to ensure that ACR guidelines and recommendations remain up to date, the ACR Quality of Care Committee will solicit periodic updates to these recommendations depending on the availability of new therapies, new evidence on the benefits and harms of existing treatments, changing opinions on what patient outcomes are considered important, and changes in policies on the resources available for health care.

ACR Recommendations for the Use of Nonbiologic and Biologic DMARDs in RA

Indications for starting or resuming a nonbiologic or biologic DMARD. These ACR recommendations focus on the use of nonbiologic and biologic therapies for the treatment of RA on the background of optimal and appropriate use of nonmedical therapies (e.g., physical and occupational therapies) as well as antiinflammatory pharmacologic interventions (e.g., nonsteroidal antiinflammatory drugs [NSAIDs], intraarticular and oral glucocorticoids). Glucocorticoids, NSAIDs, and other analgesics, despite their frequent use in RA, were not part of the ACR charge or the purview of this endeavor and are not included in these recommendations.

The recommendations developed focus on the initiation of drug therapy or indications to resume drug therapy in RA. The recommendations made in the text for when to start or resume a therapy are discussed predominately “by drug” but are not mutually exclusive based on overlapping indications for different drugs. In contrast, the tables and figures as well as discussion of all the contraindications and safety considerations provide the recommendations from the “by patient” perspective. Further, when different drugs were similarly recommended for a particular clinical circumstance, their order of presentation was alphabetical and not listed in a specific order of preference. For patients currently receiving DMARDs (both nonbiologic and biologic), decisions about switching to or adding alternative DMARDs are not usually addressed by these current recommendations. The only exception is the recommendation to use biologic DMARDs only after failure of nonbiologic DMARDs.

Recommendations to add or switch among nonbiologic DMARDs were considered by the panel, but the findings were not consistent, in large part due to a near total absence of evidence to support these important clinical decisions. Thus, the CEP voted not to include these recommendations in this initial document. It is important that RA patients be seen regularly (i.e., at intervals more frequent than those that define disease duration) to assess disease activity, evaluate disease severity, and determine whether alternative therapies are warranted. Because there was no evidence to support a specific recommendation on the frequency of provider visits, the TFP did not recommend a specific and potentially arbitrary time frame.

Although there are other nonbiologic and biologic DMARDs that are either FDA approved or occasionally used for treating RA, only the nonbiologic agents hydroxychloroquine, leflunomide, methotrexate, minocycline, and sulfasalazine, and the biologics abatacept, adalimumab, etanercept, infliximab, and rituximab are included in these recommendations. The remaining DMARDs were not included because either: 1) they were not subjected to a systematic review of the literature due to their very infrequent use (<5% of RA patients, e.g., anakinra) and/or the high incidence of adverse events when they are used (cyclophosphamide, D-penicillamine, staphylococcal immunoadsorption column, tacrolimus) (36,37), or 2) they were reviewed and evaluated by the TFP but not recommended for patients who were to start or resume treatment with

DMARDs (anakinra, azathioprine, cyclosporine, organic gold).

For each disease duration interval, the recommendations are stratified by features of poor prognosis and are further divided into patients with low, moderate, or high disease activity (see definitions listed previously and Table 1). Levels of evidence supporting each of the agreed-upon recommendations are shown in Appendix F (available at the *Arthritis Care & Research* Web site at <http://www.interscience.wiley.com/jpages/0004-3591:1/suppmat/index.html>).

Nonbiologic DMARD therapy. To maintain simplicity in these recommendations, the TFP considered only patients who had never received DMARDs. Recommendations for nonbiologic therapy are divided into those for patients with RA of varying disease duration, as defined by duration of <6 months, 6–24 months, and >24 months (Figure 2).

There are more than 170 possible dual-DMARD or triple-DMARD combinations among the 5 nonbiologic drugs considered in these recommendations. The TFP considered only combinations that were best supported by evidence and/or were used most commonly, including methotrexate plus hydroxychloroquine, methotrexate plus sulfasalazine, methotrexate plus leflunomide, sulfasalazine plus hydroxychloroquine, and sulfasalazine plus hydroxychloroquine plus methotrexate. For patient-specific circumstances, the reader is referred to the appropriate figures and tables.

Leflunomide or methotrexate. The TFP recommended the initiation of methotrexate or leflunomide monotherapy for patients with all disease durations and for all degrees of disease activity, irrespective of poor prognostic features (for methotrexate, level A/B evidence for a poor prognosis, high disease activity; level A evidence for a poor prognosis, moderate disease activity, short duration [38–47]; for leflunomide, level A evidence for a poor prognosis, high disease activity, longer disease duration [48–51]; for all other clinical scenarios in this circumstance, level C or level C* evidence).

Hydroxychloroquine or minocycline. Hydroxychloroquine monotherapy was recommended for patients without poor prognostic features, with low disease activity, and with disease duration ≤ 24 months. Minocycline monotherapy was recommended for patients without poor prognostic features, with low disease activity, and with short disease duration (level C* evidence) (52–59).

Sulfasalazine. Sulfasalazine monotherapy was recommended for patients with all disease durations and without poor prognostic features and included those with all degrees of disease activity (43,44,51,56,60–64) (level B evidence for longer disease duration, without features of poor prognosis, and moderate disease activity [63]; level C* evidence for all other clinical scenarios in this circumstance). Other circumstances in which sulfasalazine monotherapy is recommended for patients with poor prognostic features are shown in Figure 2 (level C* evidence) (51,56,60,61,64).

Dual-DMARD combinations. The two-drug combination of methotrexate plus hydroxychloroquine was recommended for patients with moderate to high disease activity irrespective of disease duration or poor prognostic features

(level B evidence for high disease activity, longer disease duration, with poor prognostic features) (65,66). The combination of methotrexate plus hydroxychloroquine was also recommended for patients with longer disease duration and low disease activity, independent of prognostic features (level C* evidence).

Methotrexate plus leflunomide was recommended for patients with intermediate or longer disease duration (≥ 6 months), regardless of prognostic features as long as disease activity was high (level B evidence for longer disease duration, with poor prognostic features) (48). Figures 2B and C list other circumstances in which this combination is recommended (level C* evidence).

Methotrexate plus sulfasalazine was recommended in patients with all disease durations if they had high disease activity and poor prognostic features (level A evidence for durations <6 months and >24 months, level C* evidence for intermediate disease duration [43,44,46,65,67]). See Figures 2B and C for other circumstances in which this combination was recommended (level C* evidence) (65).

The combination of hydroxychloroquine plus sulfasalazine was recommended in only one situation: intermediate disease duration (6–24 months) in patients with high disease activity but without poor prognostic features (level C* evidence).

Triple-DMARD combinations. The 3-drug combination therapy of sulfasalazine plus hydroxychloroquine plus methotrexate was recommended for all patients with poor prognostic features and moderate or high levels of disease activity, regardless of disease duration (level A evidence for high disease activity and longer disease duration, level C* evidence for all other clinical scenarios in this circumstance) (47,65). See Figures 2B and C for the circumstances in which this combination was recommended for patients with low disease activity or without poor prognostic features (level C* evidence) (65).

Biologic DMARDs. Recommendations for the use of biologic DMARDs are divided into those for patients with RA for <6 months (Figure 3A) and those with RA for ≥ 6 months (Figures 3B and C). Figure 3A is divided differently from the other figures. It is separated into low or moderate disease activity for <6 months and high disease activity for <3 months and for 3–6 months. The figure stratifies the use of anti-TNF α agents for durations of <3 months to make the recommendations more consonant with the scientific evidence for anti-TNF α agents (level C* evidence) (68–76). Note that a duration of <3 months or a duration of 3–6 months still refers to early disease in the context of these recommendations.

Anti-TNF α agents in early RA. The TFP limited its recommendation for the use of anti-TNF α agents (interchangeably) with methotrexate in patients with early RA to those who had never received DMARDs and had high disease activity (level C* evidence). Patients with early RA and only low or moderate disease activity were not considered candidates for biologic therapy (Figure 3A). The use of an anti-TNF agent in combination with methotrexate was recommended if high disease activity was present for <3 months with features of both a poor prognosis and an absence of either barriers related to treatment cost and no insurance restrictions to accessing medical care (68,70,72,74). This decision by the TFP and CEP was sup-




Figure 2. Recommendations on indications for the use of nonbiologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients who have never received DMARDs. These recommendations do not specifically include the potential role of glucocorticoids or nonsteroidal antiinflammatory drugs in the management of patients with RA. Therapies are listed alphabetically. **A**, disease duration <6 months. **B**, disease duration of 6–24 months. **C**, disease duration of >24 months. † = definitions of disease activity are provided in Table 1; ‡ = includes functional limitation (defined using standard measurement scales such as Health Assessment Questionnaire score or variations of this scale), extraarticular disease (e.g., presence of rheumatoid nodules, secondary Sjögren’s syndrome, RA vasculitis, Felty’s syndrome, and RA lung disease), rheumatoid factor positivity, positive anti-cyclic citrullinated peptide antibodies, or bony erosions by radiography; § = only recommended for patients with high disease activity with features of poor prognosis; || = only recommended for patients with moderate disease activity irrespective of prognostic features and patients with high disease activity without features of poor prognosis; # = only recommended for patients with high disease activity without features of poor prognosis; HCQ = hydroxychloroquine; LEF = leflunomide; MTX = methotrexate; SSZ = sulfasalazine; MIN = minocycline.




Figure 3. Recommendations on indications for the use of biologic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA). These recommendations do not specifically include the potential role of glucocorticoids or nonsteroidal antiinflammatory drugs in the management of patients with RA. Therapies are listed alphabetically. **A**, patients with RA <6 months, **B**, patients with RA \geq 6 months who failed prior MTX monotherapy, **C**, patients with RA disease duration of \geq 6 months who failed prior MTX combination therapy or after sequential administration of other nonbiologic DMARDs. † = definitions of disease activity are provided in Table 1; ‡ = includes functional limitation (defined using standard measurement scales such as Health Assessment Questionnaire score or variations of this scale), extraarticular disease (e.g., presence of rheumatoid nodules, secondary Sjögren's syndrome, RA vasculitis, Felty's syndrome, and RA lung disease), rheumatoid factor positivity, positive anti-cyclic citrullinated peptide antibodies, or bony erosions by radiography; § = only recommended for patients with high disease activity with features of poor prognosis; MTX = methotrexate; TNF = tumor necrosis factor.

ported by the results of pharmacoeconomic evaluations conducted on US populations (77–79).

Anti-TNF α agents in intermediate- and longer-duration RA. In intermediate-duration and longer-duration RA, the TFP recommended the use of the anti-TNF α agents (interchangeably) in patients for whom prior methotrexate monotherapy led to an inadequate response, with moderate disease activity and features of a poor prognosis, and for patients with high disease activity, irrespective of prognostic features. The TFP also recommended use of anti-TNF α agents (interchangeably) in patients for whom prior methotrexate therapy was used in combination, or if sequential administration of other nonbiologic DMARDs led to an inadequate response with at least moderate residual

disease activity irrespective of prognostic features (level A evidence for high disease activity) (74,76,80–101) (Figure 3C). The anti-TNF α agents (etanercept, infliximab, and adalimumab) are efficacious in improving disease activity, function, and quality of life and/or retarding radiographic progression when used alone (83,89), in combination with methotrexate (80,81,96–99,102–108), or in patients for whom treatment with DMARDs other than methotrexate led to an inadequate response (93,109). Although the majority of clinical trials have focused on adding biologic agents to methotrexate, no distinction was made by the panel regarding the decision to add biologic agents to methotrexate or to substitute for methotrexate with other nonbiologic DMARDs.

Abatacept. The TFP recommended the use of abatacept in patients for whom methotrexate in combination with DMARDs or sequential administration of other nonbiologic DMARDs led to an inadequate response, and with at least moderate disease activity and features of a poor prognosis (level A evidence for high disease activity) (110–112) (Figure 3C).

Rituximab. The TFP recommended the use of rituximab in patients for whom methotrexate in combination with DMARDs or sequential administration of other nonbiologic DMARDs led to an inadequate response, with high disease activity and features of a poor prognosis (level A evidence for high disease activity) (113–115) (Figure 3C).

Biologic therapy combinations. The TFP did not recommend combinations of biologic agents, based in part on data suggesting a higher rate of adverse events with combinations and/or lack of additive efficacy (108,116).

Contraindications to the use of nonbiologic and biologic DMARDs. The data supporting recommendations on therapeutic contraindications (Table 2) were derived primarily from observational studies, and to a lesser degree from evidence from RCTs. Many of these studies did not specifically address the questions of relevance. Therefore, the recommendations could not be derived directly from the evidence but required synthesis of the data from studies plus extrapolation to the specific clinical scenarios under consideration. As a result, all of the contraindication recommendations were graded as level C or level C* evidence, except where noted otherwise.

Infectious disease and/or pneumonitis contraindications. The TFP recommended that neither leflunomide, methotrexate, nor biologic agents should be initiated or resumed in the presence of active bacterial infection (or a bacterial infection currently requiring antibiotic therapy), active TB (or latent TB infection prior to starting preventive therapy), active herpes zoster infection, or active life-threatening fungal infections. It was noted that DMARDs could be started shortly after a bacterial infection had been successfully treated or had resolved fully. In addition, the TFP recommended against the use of all biologic agents when severe upper respiratory tract infections (bacterial or viral) or nonhealed infected skin ulcers were present. Although the data were somewhat inconsistent, with some studies refuting an infectious disease association (76,81, 93,99,117–119), the preponderance of the evidence (70,96, 117,120–129) suggested a higher rate of serious bacterial infections with the use of biologic agents compared with nonbiologic DMARDs. Although the panel considered contraindications for RA therapy in the setting of human immunodeficiency virus, no recommendations concerning contraindications were issued.

Although the relationship between methotrexate and interstitial lung disease is unclear, the TFP stated that methotrexate was contraindicated in the presence of clinically important RA-associated pneumonitis or interstitial lung disease of unknown cause (48,130–140). The TFP made no recommendation regarding the need to obtain a baseline chest radiograph prior to the initiation of methotrexate.

Hematologic and oncologic contraindications. The TFP recommended that, in general, neither leflunomide nor methotrexate should be resumed or started if the white blood cell count was $<3,000/\text{mm}^3$. Felty's syndrome and large granular lymphocyte syndrome accompanying RA were possible exceptions to this contraindication (141–143). If the platelet count was $<50,000$ per cubic milliliter, the TFP recommended that there were contraindications to the initiation or resumption of therapy with leflunomide, methotrexate, and sulfasalazine. Both leflunomide and methotrexate were contraindicated if there was a history of myelodysplasia (e.g., preleukemia) or if lymphoproliferative disease had been diagnosed and/or treated within the last 5 years. For biologic therapy, the TFP recommended that anti-TNF α agents were contraindicated in patients with prior lymphoproliferative disease that had been diagnosed and/or treated within the last 5 years (76,80,144–149). The TFP votes did not endorse any specific recommendation regarding the association of nonbiologic or biologic DMARDs with malignancies other than those associated with lymphoproliferative disorders.

Cardiac contraindications. The TFP endorsed moderate or severe heart failure (New York Heart Association class III–IV with reduced ejection fraction [150]) as a contraindication for anti-TNF α agents. Class III–IV heart failure is one of the few contraindication recommendations for which RCT data in non-RA patients provide direct evidence of a possible risk association with anti-TNF α agents (level B evidence) (151,152).

Liver contraindications. Abnormal liver transaminases. When the levels of liver transaminases (aspartate aminotransferase or alanine aminotransferase) were greater than 2-fold the upper limit of normal, the TFP recommended that the initiation or resumption of leflunomide, methotrexate, and sulfasalazine was contraindicated (although recommendations on when to discontinue are not provided). There are a large number of studies addressing leflunomide (48,50,61,132,153,154), methotrexate (41,43, 46,48,49,130–132,134–137,154–179), and sulfasalazine (44,56,60,61,63,153,180,181).

Acute hepatitis B or C. In the presence of acute hepatitis B or C, treatment with methotrexate, leflunomide, sulfasalazine, minocycline, and biologic agents was contraindicated by the TFP.

Chronic hepatitis B or C. In the presence of chronic hepatitis B or C (treated or untreated), the severity of compromised liver function was considered by the TFP as a key factor in making therapeutic decisions. The Child-Pugh scoring system for chronic liver disease (182–184) was used based on the advice of our expert advisor in the field of hepatology. This system is a liver disease severity instrument used to determine the prognosis of chronic liver disease. It is based on the serum albumin and total bilirubin levels, the prothrombin time, the presence or absence of ascites, and the presence or absence of encephalopathy. Child-Pugh class C is associated with a 1-year survival rate of 50%, whereas patients with Child-Pugh classes A or B have a 5-year survival rate of 70–80%.

The recommendations for nonbiologic DMARDs in patients with chronic hepatitis B or C were stratified based on the type of hepatitis, the Child-Pugh grade, and

Table 2. Recommendations for contraindications to starting or resuming therapy with nonbiologic and biologic disease-modifying antirheumatic drugs in RA patients*

Organ system and contraindication	ABA	Anti-TNF α	HCQ	LEF	MTX	MIN	RIT	SSZ
Infectious diseases and pneumonitis								
Acute serious bacterial infection or infection, currently receiving antibiotics	X	X	-	X	X	-	X	-
Upper respiratory tract infection (presumed viral) with fever (>101°F)	X	X	-	-	-	-	X	-
Nonhealed infected skin ulcer	X	X	-	-	-	-	X	-
Latent TB infection prior to initiation of latent TB initiation treatment, or active TB disease prior to completing a standard regimen of anti-TB therapy†	X	X	-	X	X	-	X	-
Active life-threatening fungal infection	X	X	-	X	X	-	X	-
Active herpes-zoster viral infection	X	X	-	X	X	-	X	-
Interstitial pneumonitis (due to RA or unknown cause) or clinically significant pulmonary fibrosis	-	-	-	-	X	-	-	-
Hematologic and oncologic								
White blood cell count <3,000/mm ³ ‡	-	-	-	X	X	-	-	-
Platelet count <50,000/mm ³	-	-	-	X	X	-	-	X
Myelodysplasia	-	-	-	X	X	-	-	-
Treated lymphoproliferative disease of ≤ 5 years	-	X	-	X	X	-	-	-
Cardiac								
Moderate to severe heart failure (NYHA III or IV) and left ventricular ejection fraction <50%§	-	X	-	-	-	-	-	-
Liver								
Liver transaminase level 2 times the upper limit of normal	-	-	-	X	X	-	-	X
Acute hepatitis B or C viral infection	X	X	-	X	X	X	X	X
Chronic hepatitis B viral infection, receiving therapy¶								
Child-Pugh class A#	-	-	-	X	X	-	-	-
Child-Pugh class B or C	X	X	-	X	X	X**	X	X**
Chronic hepatitis B viral infection, not receiving therapy								
Child-Pugh class A	-	-	-	X	X	X	-	X
Child-Pugh class B or C	X	X	X**	X	X	X	X	X
Chronic hepatitis C viral infection, receiving therapy								
Child-Pugh class A	-	-	-	X	X	-	-	-
Child-Pugh class B or C	X	X	-	X	X	X**	X	X
Chronic hepatitis C viral infection, not receiving therapy								
Child-Pugh class A	-	-	-	X	X	X	-	-
Child-Pugh class B or C	X	X	X**	X	X	X	X	X
Renal								
Creatinine clearance <30 ml/minute	-	-	-	-	X	-	-	-
Neurologic								
Multiple sclerosis or other demyelinating disorder	-	X	-	-	-	-	-	-
Pregnancy and breastfeeding								
Planning for or current pregnancy	-	-	-	X	X	X	-	-
Breastfeeding	-	-	-	X	X	X	-	-

* The presence of a dash does not indicate an affirmative recommendation for the use of the drug in a particular clinical circumstance. Please see the section RAND/UCLA appropriateness method. Therapies are listed alphabetically. RA = rheumatoid arthritis; ABA = abatacept; anti-TNF α = anti-tumor necrosis factor α ; HCQ = hydroxychloroquine; LEF = leflunomide; MTX = methotrexate; MIN = minocycline; RIT = rituximab; SSZ = sulfasalazine; X = contraindication; TB = tuberculosis.

† TB treatment and full adherence as recommended by TB expert and considered successfully treated.

‡ Felty's syndrome and large granular lymphocyte syndrome as causes of neutropenia are possible exceptions.

§ New York Heart Association (NYHA) class III = patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain. NYHA class IV = patient with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.

¶ Therapy defined as antiviral regimen deemed appropriate by expert in liver diseases.

The Child-Pugh classification liver disease scoring system is based on the presence of albumin, ascites, total bilirubin, prothrombin time, and encephalopathy. Patients with a score ≥ 10 (in the class C category) have a prognosis with 1-year survival of $\sim 50\%$. Patients with class A or B have a better prognosis of 5 years, with a survival rate of 70–80% (182).

** Contraindicated for Child-Pugh class C only.

whether or not antiviral agents to treat hepatitis had been initiated (Table 2). When treating patients with chronic hepatitis B or C, physicians need to consider the risks and

benefits for all DMARDs. For certain DMARDs, such as hydroxychloroquine, the TFP discussed uncommon but reported concerns about the use of these agents in the

setting of severe underlying liver injury, defined as Child-Pugh class C (185,186).

In the setting of treated chronic hepatitis B, leflunomide and methotrexate were contraindicated by the TFP for all Child-Pugh classifications, and minocycline and sulfasalazine were contraindicated for Child-Pugh class C.

In untreated chronic hepatitis B, leflunomide, methotrexate, minocycline, and sulfasalazine were contraindicated by the TFP for all Child-Pugh classifications, and hydroxychloroquine was contraindicated for Child-Pugh class C.

In treated chronic hepatitis C, leflunomide and methotrexate were contraindicated for all Child-Pugh classifications, minocycline was contraindicated for Child-Pugh class C, and sulfasalazine was contraindicated for Child-Pugh classes B and C.

In untreated chronic hepatitis C, leflunomide, methotrexate, and minocycline were contraindicated for all Child-Pugh classifications, sulfasalazine was contraindicated for Child-Pugh classes B and C, and hydroxychloroquine was contraindicated for Child-Pugh class C.

The recommendations concerning biologic DMARDs in patients with chronic hepatitis B or C are as follows: although TNF α blockade occasionally has been used in patients with chronic hepatitis, particularly when antiviral therapy is used concomitantly (187,188), the TFP recommended that biologic agents were contraindicated in both chronic hepatitis B and C, whether treated or untreated for those with significant liver injury, defined as chronic Child-Pugh classes B or C (189,190).

Renal contraindications. The TFP recommended that starting or resuming methotrexate was contraindicated if the estimated creatinine clearance was <30 ml/minute (167,191,192). One study addressed adverse renal events when using sulfasalazine (191) and this study found that sulfasalazine was not associated with adverse renal effects. Nevertheless, the TFP did not reach consensus on sulfasalazine's use in the face of renal impairment.

Neurologic contraindications. The TFP recommended against the use of anti-TNF α agents in the setting of multiple sclerosis or demyelinating disorders. There are limited observations, from both RCTs and cohort studies, that patients exposed to anti-TNF α therapy developed demyelinating disorders (level B evidence) (83,106).

Contraindications in pregnancy and breastfeeding. Leflunomide, methotrexate, and minocycline were considered by the TFP to be contraindicated in RA patients planning for pregnancy or during pregnancy, due to the potential teratogenicity of these drugs (193,194). The TFP recommended against the initiation or resumption of these drugs during breastfeeding (195–198). Because of conflicting evidence (199–208), the TFP deliberations did not yield any specific recommendation regarding the use of biologic DMARDs in these clinical scenarios.

Perioperative infectious risk. The TFP recommended that biologic agents should not be used during the perioperative period, for at least 1 week prior to and 1 week after surgery (level C* evidence) (Table 3) (117,209–212). It was recommended that this decision should be further tempered by the pharmacokinetic properties of a given biologic agent (e.g., longer periods of time off therapy may be

Table 3. Recommendations for withholding biologic disease-modifying antirheumatic drugs in preoperative and perioperative periods*

Therapeutic agent	Withhold medication for ≥ 1 week before/after surgery
Abatacept†	X
Anti-tumor necrosis factor α †	X
Rituximab†	X

* Therapies are listed alphabetically. X = contraindication.
 † When considering discontinuation, the pharmacokinetics of the drugs and the infectious risk of the surgery being performed should be considered.

appropriate when using agents with longer half-lives), and the type of surgery. The panel articulated less concern for withholding therapy for patients undergoing minor surgeries with a low risk of infection (e.g., cataract operations). The TFP votes were influenced by an absence of consistent evidence and yielded no recommendation regarding the use of nonbiologic DMARDs during the perioperative period (213–224).

Safety monitoring, risk surveillance, and preventive immunizations. *Nonbiologic DMARDs.* The ACR has previously published recommendations on safety monitoring for the use of nonbiologic DMARDs (225,226). These recommendations were grounded in the recognition that there are safety concerns with several of the commonly used nonbiologic DMARDs that may be circumvented or attenuated by the early identification of toxicity. This includes using routine laboratory testing such as complete blood counts, serum creatinine measurement, and periodic determination of liver transaminase levels. Despite strong association of certain DMARDs with specific toxicities (227–230), evidence supporting specific temporal monitoring recommendations remains elusive and is partially driven by practical issues such as a need to avoid overly frequent phlebotomies or physician visits. The recommended frequency of testing and the relationship of testing intervals to both DMARDs and duration remain rather empiric and are largely based on expert consensus (level C and level C* evidence).

When starting or resuming therapy with a nonbiologic or biologic DMARD (baseline), obtaining a complete blood count, liver transaminase levels, and serum creatinine levels was recommended by the TFP for all therapies (Table 4). In addition, for both leflunomide and methotrexate, screening for hepatitis B and C was recommended for patients at higher risk (e.g., history of intravenous drug abuse) (231,232).

The TFP recommended influenza vaccinations for patients prior to starting therapy with all nonbiologic DMARDs and pneumococcal vaccinations for patients starting leflunomide, methotrexate, or sulfasalazine (233–235), if the patient's vaccinations were not current. This recommendation was in accordance with the Centers for Disease Control and Prevention (CDC) general recommen-

Table 4. Recommendations on baseline evaluation for starting, resuming, or significant dose increase of a therapy in patients with rheumatoid arthritis receiving nonbiologic and biologic disease-modifying antirheumatic drugs*

Therapeutic agents	CBC	Liver transaminases	Creatinine	Hepatitis B and C testing†	Ophthalmologic examination‡
Hydroxychloroquine	X	X	X		X
Leflunomide	X	X	X	X	
Methotrexate	X	X	X	X	
Minocycline	X	X	X		
Sulfasalazine	X	X	X		
All biologic agents	X	X	X		

* Therapies are listed alphabetically. CBC = complete blood count; X = recommend test.
† If hepatitis risk factors are present (e.g., intravenous drug abuse, multiple sex partners in the previous 6 months, health care personnel). Evaluation might include tests for hepatitis B surface antigen, hepatitis B antibodies, hepatitis B core antibodies, and/or hepatitis C antibodies.
‡ Ophthalmologic examination is recommended within the first year of treatment. For patients in higher-risk categories (e.g., liver disease, concomitant retinal disease, and age ≥ 60 years), the American Academy of Ophthalmology recommends an annual followup eye examination (239).

dations for appropriate use of these vaccinations in persons with chronic illnesses (Table 5) (236,237). Hepatitis B vaccination was recommended if risk factors for this disease existed (231,232) and if hepatitis B vaccination had not previously been administered (233,234,238).

It was recommended that all patients starting therapy with hydroxychloroquine should have a complete ophthalmologic examination within the first year of treatment. This should include examination of the retina through a dilated pupil and testing of central visual field sensitivity by either a self-testing grid chart (Amsler grid) or automated threshold central visual field testing (Humphrey 10-2 testing). If the patient is in the low-risk category (e.g., no liver disease, no concomitant retinal disease, and age

<60 years) and these examination results are normal, the American Academy of Ophthalmology recommendation is that no further special ophthalmologic testing is needed for the next 5 years. For patients in the higher-risk category, an annual eye examination is recommended by the American Academy of Ophthalmology (239).

Following initiation of leflunomide, methotrexate, and/or sulfasalazine or when the dose of these drugs is significantly increased, complete blood counts, liver function tests, and determination of serum creatinine levels were recommended every 2–4 weeks for the next 3 months (Table 6). The TFP did not recommend any surveillance blood testing for patients receiving hydroxychloroquine or minocycline.

Table 5. Recommendations for vaccinations in patients with rheumatoid arthritis receiving nonbiologic and biologic disease-modifying antirheumatic drugs*

Therapeutic agents	Pneumococci†	Influenza‡	Hepatitis B§	Avoid live vaccinations
Hydroxychloroquine		X		
Leflunomide	X	X	X	
Methotrexate	X	X	X	
Minocycline		X		
Sulfasalazine	X	X		
All biologic agents	X	X	X	X

* Therapies are listed alphabetically. X = recommended.
† Vaccination should be considered according to recommendations of the Centers for Disease Control and Prevention (CDC), which includes all patients with chronic illness, active malignancy, immunosuppression/use of immunosuppressive drugs, diabetes mellitus, pregnancy, and chronic lung disease, independent of when rheumatoid arthritis drugs are initiated. The CDC also recommends a 1-time pneumococcal revaccination after 5 years for persons with the previously listed conditions. For persons age ≥ 65 years, 1-time revaccination is recommended if they were vaccinated ≥ 5 years previously and were age <65 years at the time of primary vaccination.
‡ Vaccination should be considered according to recommendations of the CDC, which includes all patients with chronic illness, active malignancy, immunosuppression/use of immunosuppressive drugs, diabetes mellitus, pregnancy, and chronic lung disease, independent of when rheumatoid arthritis drugs are initiated.
§ If hepatitis risk factors are present (e.g., intravenous drug abuse, multiple sex partners in the previous 6 months, health care personnel).

Therapeutic agents†	Monitoring interval based on duration of therapy		
	<3 months	3–6 months	>6 months
	Hydroxychloroquine	None after baseline	None
Leflunomide	2–4 weeks	8–12 weeks	12 weeks
Methotrexate	2–4 weeks	8–12 weeks	12 weeks
Minocycline	None after baseline	None	None
Sulfasalazine	2–4 weeks	8–12 weeks	12 weeks

* More frequent monitoring is recommended within the first 3 months of therapy or after increasing the dose, and the outer bound of the monitoring interval is recommended beyond 6 months of therapy.
 † Listed alphabetically.

Beyond 3 months of therapy with leflunomide, methotrexate, or sulfasalazine, monitoring with complete blood count, a chemistry panel, and determination of the serum creatinine levels was recommended every 8–12 weeks. Beyond 6 months of therapy, the longer time interval (e.g., 12 weeks) of the monitoring recommendation was suggested.

Biologic DMARDs. The TFP recommended periodic pneumococcal vaccinations and annual influenza vaccinations for all patients receiving biologic agents, in accordance with CDC recommendations for appropriate use and timing of these vaccinations (236,237). The panel also recommended completion of a hepatitis B vaccination se-




Figure 4. Recommendations for screening for tuberculosis (TB) among rheumatoid arthritis patients being considered for biologic disease-modifying antirheumatic drugs. * = risk factors for developing TB (adapted from the recommendations of the Centers for Disease Control and Prevention [CDC; 244,245]) include human immunodeficiency virus, fibrotic changes on chest radiography, organ transplantation, receiving the equivalent of >5 mg/day of prednisone for ≥1 month, the use of other immunosuppressive drugs such as anti-tumor necrosis factor α agents, recent immigrants (<5 years) from high prevalence countries, intravenous drug users, residents and employees of high-risk congregate settings (e.g., prisons and jails, nursing homes and other long-term care facilities for the elderly, hospitals and other health care facilities, residential facilities for patients with acquired immunodeficiency syndrome, and homeless shelters), mycobacteriology laboratory personnel, silicosis, diabetes mellitus, chronic renal failure, severe hematologic disorders (e.g., leukemias and lymphomas), carcinoma of the head or neck or lung, weight loss >10% of ideal body weight, history of gastrectomy or jejunioileal bypass; † = LTBI is a positive tuberculin skin test result with no evidence of active tuberculosis disease (adapted from the CDC recommendations).

ries if risk factors were present. The panel recognized that the immune response to influenza and pneumococcal vaccinations in patients receiving methotrexate and biologic therapies may be attenuated, although usually adequate (230,240–243). Live vaccines (e.g., varicella-zoster vaccine, oral polio, rabies) are contraindicated during biologic therapy.

TB screening for patients receiving biologic DMARDs.

The TFP recommended routine TB screening to identify latent TB infection in patients being considered for therapy with biologic agents (Figure 4). The evidence for TB testing is based on a documented higher incidence of TB following anti-TNF α therapy (117,122). To begin, the TFP recommended that clinicians should ask all RA patients being considered for biologic DMARD therapy about their potential risk factors for TB infection (see below) and, irrespective of prior BCG vaccination, should use a TB skin test as a diagnostic aid to assess the patient's probability of latent TB infection (Figure 4). It should be noted that RA patients are more likely to have false-negative skin test results because of immunosuppression; therefore, a negative TB skin test result should not be interpreted as exclusion of latent TB infection, remembering that a combination of medical history and TB skin testing plus other testing as clinically indicated always should be used. Induration \geq 5 mm following a standard TB skin test should be considered a positive response.

Patients at higher risk for having latent TB infection are those who are homeless, and those who have lived in countries with a high prevalence of TB, used intravenous drugs, or spent time in settings associated with higher rates of TB transmission (e.g., prison or health care institutions). In addition, patients with latent TB infection who were more recently infected, those with prior untreated active TB disease (or typical fibrotic lesions on chest radiography), and those with factors associated with immunosuppression are at higher risk for the progression of latent TB infection to active TB disease. In addition to RA and the use of biologic DMARDs, such factors include 1) human immunodeficiency virus infection; 2) underweight or malnourished; 3) intravenous drug use; 4) medical conditions such as diabetes mellitus, silicosis, chronic renal failure; 5) solid organ transplantation (e.g., kidney, liver, heart); 6) carcinoma of the head or neck or lung; 7) history of gastrectomy or jejunioileal bypass; and 8) prolonged use of oral glucocorticoids (244,245). All of these factors should be considered during the screening of patients prior to the initiation of biologic therapy and should continue to be considered during long-term followup of patients continuing biologic and nonbiologic immunosuppressant treatment, even if the patient's RA is well controlled. The panel also recommended retesting for latent TB infection in those patients with newly developed TB exposures.

Although the CDC has recommended that the QuantiFERON-TB Gold test (Cellestis Limited, Abbotsford, Victoria, Australia) may be used in most circumstances in which TB skin testing is currently employed, no specific recommendation was made by the TFP regarding the use of the QuantiFERON-TB Gold test in RA at this time.

Further research is needed to determine the sensitivity and specificity of this new test to identify latent TB infection in immunosuppressed patients (246,247). Additionally, the QuantiFERON-TB Gold test is not yet routinely available throughout the US, limiting its current usage. Parenthetically, the TFP recognized that the QuantiFERON-TB Gold test may play a special role in evaluating patients who have previously received the BCG vaccine.

These ACR recommendations defer the decision to initiate anti-TB therapy to physicians possessing sufficient expertise in TB management. In general, patients with latent TB infection should begin preventive therapy before starting their anti-TNF α therapy (248). The CDC suggests that the preferred regimen for management of latent TB infection is a 9-month course of daily isoniazid (245). The CDC also suggests delaying anti-TNF α therapy until isoniazid treatment has been initiated but does not specify an optimal time period of delay (249). Observational studies suggest anti-TNF α therapy can be safely started 1 month after starting isoniazid treatment (250,251). The British Thoracic Society also has provided recommendations on this issue (252). Treatment with isoniazid does not eliminate all cases of anti-TNF α -associated TB, and clinicians should remain vigilant for active TB in any anti-TNF α -treated patient in whom constitutional or chronic respiratory symptoms develop during anti-TNF α therapy.

Conclusion

Using a formal group process and the scientific evidence as much as possible, we provide recommendations for the use of nonbiologic and biologic therapies in patients with RA when starting or resuming these therapies. These recommendations are not meant to take the place of personalized patient care and are intended to help guide therapy rather than proscribe appropriate therapies. The recommendations are extensive but not comprehensive, and it is intended that they will be regularly updated to reflect the rapidly growing scientific evidence in this area along with changing practice patterns in rheumatology.

Addendum. Therapies that were approved after the original literature review are not included in these recommendations.

AUTHOR CONTRIBUTIONS

Dr. Furst had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study design. Saag, Teng, Patkar, Anuntiyo, Finney, Curtis, Paulus, Mudano, Pisu, Allison, MacLean, Moreland, Furst.

Acquisition of data. Saag, Teng, Patkar, Anuntiyo, Finney, Curtis, Mudano, Pisu, Mikuls, Moreland, Turkiewicz, Furst.

Analysis and interpretation of data. Saag, Teng, Patkar, Anuntiyo, Finney, Curtis, Paulus, Mudano, Pisu, Allison, Suarez Almazor, Bridges, Chatham, Hochberg, Mikuls, Moreland, O'Dell, Turkiewicz, Furst.

Manuscript preparation. Saag, Teng, Patkar, Anuntiyo, Finney, Curtis, Paulus, Mudano, Pisu, Outman, Suarez Almazor, Bridges, Hochberg, MacLean, Mikuls, Moreland, O'Dell, Turkiewicz, Furst.

Statistical analysis. Saag, Teng, Patkar, Curtis, Mudano.

Project management. Teng, Patkar, Elkins-Melton.

American College of Rheumatology representative to the Core Expert Panel. Hochberg.

REFERENCES

- Pressman Lovinger S. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost. *JAMA* 2003;289:3229–30.
- Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. *N Engl J Med* 2006;355:704–12.
- American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. *Arthritis Rheum* 2002;46:328–46.
- The Appraisal of Guidelines for Research and Evaluation (AGREE) Collaboration. Introduction to the AGREE Collaboration. 2001. URL: www.agreecollaboration.org.
- Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA Appropriateness Method user's manual. Santa Monica (CA): RAND Corporation; 2001.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1–12.
- Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. *Ottawa (ON): Ottawa Health Research Institute; 1999*.
- Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* 2005;64:669–81.
- Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. *Rheum Dis Clin North Am* 2006;32:9–44.
- Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. *Arthritis Rheum* 2005;52:2625–36.
- Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;38:727–35.
- Pincus T. The American College of Rheumatology (ACR) core data set and derivative "patient only" indices to assess rheumatoid arthritis. *Clin Exp Rheumatol* 2005;23(5 Suppl 39):S109–13.
- Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. *J Rheumatol* 2005;32:2016–24.
- Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS-II). *J Rheumatol* 2005;32:2410–5.
- Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. *Arthritis Rheum* 2005;52:3873–9.
- Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. *Clin Rheumatol* 2007;26:201–4.
- Ates A, Kinikli G, Turgay M, Akay G, Tokgoz G. Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. *Clin Rheumatol* 2007;26:538–45.
- Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. *Ann Rheum Dis* 2006;65:453–8.
- Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. *Ann Rheum Dis* 2003;62:120–6.
- Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. *Ann Rheum Dis* 2003;62:427–30.
- Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. *Ann Rheum Dis* 2002;61:290–7.
- Gossec L, Dougados M, Goupille P, Cantagrel A, Sibilia J, Meyer O, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. *Ann Rheum Dis* 2004;63:675–80.
- Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. *Ann Rheum Dis* 2003;62:611–6.
- Lindqvist E, Saxne T, Geborek P, Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. *Ann Rheum Dis* 2002;61:1055–9.
- Brook A, Fleming A, Corbett M. Relationship of radiological change to clinical outcome in rheumatoid arthritis. *Ann Rheum Dis* 1977;36:274–5.
- Cohen JD, Dougados M, Goupille P, Cantagrel A, Meyer O, Sibilia J, et al. Health Assessment Questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis. *J Rheumatol* 2006;33:1936–41.
- Corbett M, Dalton S, Young A, Silman A, Shipley M. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. *Br J Rheumatol* 1993;32:717–23.
- Scott DL, Coulton BL, Popert AJ. Long term progression of joint damage in rheumatoid arthritis. *Ann Rheum Dis* 1986;45:373–8.
- Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. *Arthritis Rheum* 1998;41:1571–82.
- Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. *Arthritis Rheum* 1998;41:1072–82.
- McMahon MJ, Hillarby MC, Clarkson RW, Hollis S, Grennan DM. Major histocompatibility complex variants and articular disease severity in rheumatoid arthritis. *Br J Rheumatol* 1993;32:899–902.
- McGory ML, Shekelle PG, Rubenstein LZ, Fink A, Ko CY. Developing quality indicators for elderly patients undergoing abdominal operations. *J Am Coll Surg* 2005;201:870–83.
- Shekelle P. The Appropriateness Method. *Med Decis Making* 2004;24:228–31.
- Shekelle PG, Park RE, Kahan JP, Leape LL, Kamberg CJ, Bernstein SJ. Sensitivity and specificity of the RAND/UCLA Appropriateness Method to identify the overuse and underuse of coronary revascularization and hysterectomy. *J Clin Epidemiol* 2001;54:1004–10.
- Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al, the American College of Cardiology, the American Heart Association Task Force on Practice Guidelines, the American College of Chest Physicians, the International Society for Heart and Lung Transplantation, and the Heart Rhythm Society. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. *Circulation* 2005;112:e154–235.
- Edwards CJ, Arden NK, Fisher D, Saperia JC, Reading I, Van Staa TP, et al. The changing use of disease-modifying anti-

- rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. *Rheumatology* (Oxford) 2005;44:1394–8.
37. Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, et al. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. *Curr Med Res Opin* 2006;22:169–83.
 38. Wendt T, Eidner T, Braunig E, Hein G. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. *Eur J Med Res* 1999;4:442–8.
 39. Jeurissen ME, Boerbooms AM, van de Putte LB, Doesburg WH, Mulder J, Rasker JJ, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty-eight-week randomized, double-blind trial. *Arthritis Rheum* 1991;34:961–72.
 40. Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, and The METGO Study Group. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. *Arthritis Rheum* 2005;52:1360–70.
 41. Rau R, Herborn G, Karger T, Menninger H, Elhardt D, Schmitt J. A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: an interim report on 102 patients after 12 months. *Semin Arthritis Rheum* 1991;21(2 Suppl 1):13–20.
 42. Rau R, Herborn G, Karger T, Menninger H, Elhardt D, Schmitt J. A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. *J Rheumatol* 1991;18:328–33.
 43. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomized, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. *Ann Rheum Dis* 1999;58:220–5.
 44. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. *Br J Rheumatol* 1997;36:1082–8.
 45. Willkens RF, Urowitz MB, Stablein DM, McKendry RJ Jr, Berger RG, Box JH, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. *Arthritis Rheum* 1992;35:849–56.
 46. Haagsma CJ, van Riel PL, de Rooij DJ, Vree TB, Russel FJ, van 't Hof MA, et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. *Br J Rheumatol* 1994;33:1049–55.
 47. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. *N Engl J Med* 1996;334:1287–91.
 48. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al, and the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. *Arch Intern Med* 1999;159:2542–50.
 49. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2002;137:726–33.
 50. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. *Arthritis Rheum* 1995;38:1595–603.
 51. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al, and the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. *Lancet* 1999;353:259–66.
 52. Davis MJ, Dawes PT, Fowler PD, Clarke S, Fisher J, Shadforth MF. Should disease-modifying agents be used in mild rheumatoid arthritis? *Br J Rheumatol* 1991;30:451–4.
 53. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. *Am J Med* 1995;98:156–68.
 54. Clark P, Casas E, Tugwell P, Medina C, Gheno C, Tenorio G, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial. *Ann Intern Med* 1993;119:1067–71.
 55. O'Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. *Arthritis Rheum* 2001;44:2235–41.
 56. Nuver-Zwart IH, van Riel PL, van de Putte LB, Gribnau FW. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. *Ann Rheum Dis* 1989;48:389–95.
 57. Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al, and the MIRA Trial Group. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. *Ann Intern Med* 1995;122:81–9.
 58. Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA. Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. *Arthritis Rheum* 1994;37:629–36.
 59. O'Dell JR, Haire CE, Palmer W, Drymalski W, Wees S, Blakely K, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 1997;40:842–8.
 60. Williams HJ, Ward JR, Dahl SL, Clegg DO, Willkens RF, Oglesby T, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. *Arthritis Rheum* 1988;31:702–13.
 61. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, et al, for the European Leflunomide Study Group. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. *Ann Rheum Dis* 2001;60:913–23.
 62. Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, et al, for the European Leflunomide Study Group. Improved functional ability in patients with rheumatoid arthritis: longterm treatment with leflunomide versus sulfasalazine [published erratum appears in *J Rheumatol* 2002;29:205]. *J Rheumatol* 2001;28:1983–91.
 63. The Australian Multicentre Clinical Trial Group. Sulfasalazine in early rheumatoid arthritis. *J Rheumatol* 1992;19:1672–7.
 64. Farr M, Waterhouse L, Johnson AE, Kitas GD, Jubb RW, Bacon PA. A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis. *Clin Rheumatol* 1995;14:531–6.
 65. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2002;46:1164–70.
 66. Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. *J Rheumatol* 2002;29:1639–45.
 67. Boers M, Verhoeven AC, Markuse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheuma-

- toid arthritis [published erratum appears in *Lancet* 1998;351:220]. *Lancet* 1997;350:309–18.
68. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum* 2006;54:26–37.
69. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2005;52:27–35.
70. St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum* 2004;50:3432–43.
71. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2007;146:406–15.
72. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published errata appear in *N Engl J Med* 2001;344:76 and *N Engl J Med* 2001;344:240]. *N Engl J Med* 2000;343:1586–93.
73. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum* 2005;52:3381–90.
74. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. *Arthritis Rheum* 2002;46:1443–50.
75. Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. *J Rheumatol* 2004;31:1532–7.
76. Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. *J Rheumatol* 2005;32:1232–42.
77. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. *Arthritis Rheum* 2000;43:2316–27.
78. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. *Am J Med* 2002;113:400–8.
79. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. *J Rheumatol* 2002;29:1156–65.
80. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J, for The Etanercept Study 301 Investigators. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. *Ann Rheum Dis* 2006;65:1578–84.
81. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, and the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004;363:675–81.
82. Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. *Arthritis Rheum* 2003;48:1493–9.
83. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. *Ann Intern Med* 1999;130:478–86.
84. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. *J Rheumatol* 2006;33:854–61.
85. O'Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, et al. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. *J Rheumatol* 2006;33:213–8.
86. Perera LC, Tymms KE, Wilson BJ, Shadbolt B, Brook AS, Dorai Raj AK, et al. Etanercept in severe active rheumatoid arthritis: first Australian experience. *Intern Med J* 2006;36:625–31.
87. Van Vollenhoven RF, Klareskog L. Clinical responses to tumor necrosis factor α antagonists do not show a bimodal distribution: data from the Stockholm Tumor Necrosis Factor α Followup Registry. *Arthritis Rheum* 2003;48:1500–3.
88. Van Der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. *Ann Rheum Dis* 2006;65:328–34.
89. Van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Ann Rheum Dis* 2004;63:508–16.
90. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor- α monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. *Clin Ther* 2003;25:1700–21.
91. Ferraccioli G, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. *Ann Rheum Dis* 2002;61:358–61.
92. Flendrie M, Creemers MC, Welsing PM, van Riel PL. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis: a longitudinal observational study. *Rheumatology (Oxford)* 2005;44:472–8.
93. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor- α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). *J Rheumatol* 2003;30:2563–71.
94. Hansen KE, Cush J, Singhal A, Cooley DA, Cohen S, Patel SR, et al. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. *Arthritis Rheum* 2004;51:228–32.
95. Heiberg MS, Rodevand E, Mikkelsen K, Kaufmann C, Diriksen A, Mowinckel P, et al. Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicenter study. *Ann Rheum Dis* 2006;65:1379–83.
96. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional

- outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum* 2004;50:1400–11.
97. Maini R, St.Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: randomized phase III trial. *Lancet* 1999;354:1932–9.
 98. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis Rheum* 1998;41:1552–63.
 99. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis Rheum* 2004;50:1051–65.
 100. Sidiropoulos P, Bertsias G, Kritikos HD, Kouroumalis H, Voukouris K, Boumpas DT. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. *Ann Rheum Dis* 2004;63:144–8.
 101. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temeconidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. *Am J Med* 2005;118:515–20.
 102. Lipsky PE, van der Heijde DM, St.Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. *N Engl J Med* 2000;343:1594–602.
 103. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al, for the ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy study. *Arthritis Rheum* 2005;52:1020–30.
 104. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al, for the TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis Rheum* 2006;54:1063–74.
 105. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* 1999;340:253–9.
 106. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. *Ann Rheum Dis* 2006;65:753–9.
 107. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial [published erratum appears in *Arthritis Rheum* 2003;48:855]. *Arthritis Rheum* 2003;48:35–45.
 108. Genovese MC, Cohen S, Moreland L, Liem D, Robbins S, Newmark R, et al, for the 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. *Arthritis Rheum* 2004;50:1412–9.
 109. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al, for the Etanercept European Investigators Network (The Etanercept Study 309 Investigators). Etanercept and sulphasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulphasalazine: a double-blind comparison. *Ann Rheum Dis* 2006;65:1357–62.
 110. Emery P, Kosinski M, Li T, Martin M, Williams GR, Becker JC, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. *J Rheumatol* 2006;33:681–9.
 111. Genant HK, Peterfy C, Westhovens R, Becker JP, Aranda R, Teng J, et al. Abatacept sustains inhibition of radiographic progression over 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate: results from the long-term extension of the AIM trial [abstract]. *Ann Rheum Dis* 2006;65 Suppl II:57.
 112. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2006;144:865–76.
 113. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med* 2004;350:2572–81.
 114. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis Rheum* 2006;54:1390–400.
 115. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al, for the Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. *Ann Rheum Dis* 2005;64:913–20.
 116. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. *Arthritis Rheum* 2006;54:2807–16.
 117. Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum* 2006;54:2368–76.
 118. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. *Arthritis Rheum* 2006;54:628–34.
 119. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. *Arthritis Rheum* 2004;50:372–9.
 120. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [published erratum appears in *JAMA* 2006;295:2482]. *JAMA* 2006;295:2275–85.
 121. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. *Arthritis Rheum* 2005;52:3403–12.
 122. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis

- in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. *Arthritis Rheum* 2005;52:1986–92.
123. Baldin B, Dozol A, Spreux A, Chichmanian RM. Tuberculosis and infliximab treatment: national surveillance from January 1, 2000, through June 30, 2003. *Presse Med* 2005;34:353–7. In French.
 124. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. *Clin Infect Dis* 2006;43:717–22.
 125. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. *Ann Rheum Dis* 2003;62 Suppl 2:ii30–3.
 126. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α -neutralizing agent. *N Engl J Med* 2001;345:1098–104.
 127. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. *Clin Infect Dis* 2004;39:295–9.
 128. Perdriger A, Mariette X, Kuntz JL, Brocq O, Kara-Terki R, Le Loet X, et al, and the Club Rheumatismes et Inflammation. Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. *J Rheumatol* 2006;33:865–9.
 129. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. *Ann Rheum Dis* 2006;65:889–94.
 130. McKendry RJ, Cyr M. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a case-control study of 131 patients. *Arch Intern Med* 1988;149:685–9.
 131. Van Jaarsveld CH, Jahangier ZN, Jacobs JW, Blaauw AA, van Albada-Kuipers GA, ter Borg EJ, et al. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. *Rheumatology (Oxford)* 2000;39:1374–82.
 132. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. *Rheumatology (Oxford)* 2000;39:655–65.
 133. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. *Rheumatology (Oxford)* 2005;44:61–6.
 134. Drosos AA, Psychos D, Andonopoulos AP, Stefanaki-Nikou S, Tsiianos EB, Moutsopoulos HM. Methotrexate therapy in rheumatoid arthritis: a two year prospective follow-up. *Clin Rheumatol* 1990;9:333–41.
 135. Hanrahan PS, Scrivens GA, Russell AS. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. *Br J Rheumatol* 1989;28:147–53.
 136. Schnabel A, Reinhold-Keller E, Willmann V, Gross WL. Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. *Rheumatol Int* 1994;14:33–8.
 137. Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. *J Rheumatol* 1993;20:639–44.
 138. Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving long-term low-dose methotrexate. *Chest* 1996;109:933–8.
 139. Hilliquin P, Renoux M, Perrot S, Puechal X, Menkes CJ. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. *Br J Rheumatol* 1996;35:441–5.
 140. Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. *J Rheumatol* 1997;24:2299–303.
 141. Allen LS, Groff G. Treatment of Felty's syndrome with low-dose oral methotrexate. *Arthritis Rheum* 1986;29:902–5.
 142. Tan N, Grisanti MW, Grisanti JM. Oral methotrexate in the treatment of Felty's syndrome. *J Rheumatol* 1993;20:599–601.
 143. Wassenberg S, Herborn G, Rau R. Methotrexate treatment in Felty's syndrome. *Br J Rheumatol* 1998;37:908–11.
 144. Askling J, Foreb CM, Baecklund E, Brandt L, Backlin C, Ekblom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. *Ann Rheum Dis* 2005;64:1414–20.
 145. Feltelius N, Foreb CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, et al, for the ARTIS group. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. *Ann Rheum Dis* 2005;64:246–52.
 146. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. *Ann Rheum Dis* 2005;64:699–703.
 147. Geborek P, Crnkic M, Petersson IF, Saxne T, for the South Swedish Arthritis Treatment Group. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. *Ann Rheum Dis* 2002;61:793–8.
 148. Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during prolonged treatment with infliximab. *J Rheumatol* 2003;30:2557–62.
 149. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. *Arthritis Rheum* 2004;50:1740–51.
 150. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown; 1994. p. 253–6.
 151. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, and the Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor- α , in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 2003;107:3133–40.
 152. Mann DL, McMurray JJ, Packer M, Swedburg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation* 2004;109:1594–602.
 153. Smolen JS. Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. *Scand J Rheumatol Suppl* 1999;112:15–21.
 154. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al, for the Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. *Arthritis Rheum* 2001;44:1984–92.
 155. Cartwright VW, Michaud K, Choi HK, Wolfe F. Methotrexate, laboratory testing and risk of serious illness: analyses in 20,000 patients [abstract]. *Arthritis Rheum* 2003;48 Suppl 9:S428–9.
 156. Rau R, Karger T, Herborn G, Frenzel H. Liver biopsy findings in patients with rheumatoid arthritis undergoing long-term treatment with methotrexate. *J Rheumatol* 1989;16:489–93.
 157. Yazici Y, Erkan D, Harrison MJ, Nikolov NP, Paget SA. Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities. *Clin Exp Rheumatol* 2005;23:517–20.
 158. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical

- cal care: discontinuation is unusual and rarely the result of laboratory abnormalities. *Ann Rheum Dis* 2005;64:207–11.
159. Arnold MH, O'Callaghan J, McCredie M, Beller EM, Kelly DE, Brooks PM. Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study. *Br J Rheumatol* 1990;29:120–5.
 160. Hamilton J, McInnes IB, Thomson EA, Porter D, Hunter JA, Madhok R, et al. Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. *Ann Rheum Dis* 2001;60:566–72.
 161. Morassut P, Goldstein R, Cyr M, Karsh J, McKendry RJ. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis: a randomized, double blind 26-week trial. *J Rheumatol* 1989;16:302–6.
 162. Suarez-Almazor ME, Fitzgerald A, Grace M, Russell AS. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysin) in the treatment of rheumatoid arthritis. *J Rheumatol* 1988;15:753–6.
 163. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. *Arthritis Rheum* 1993;36:297–306.
 164. Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. *Br J Rheumatol* 1997;36:345–52.
 165. Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. *Br J Rheumatol* 1998;37:1060–8.
 166. Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. *J Rheumatol* 2004;31:1906–11.
 167. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. *Arthritis Rheum* 2004;50:364–71.
 168. Sany J, Anaya JM, Lussiez V, Couret M, Combe B, Daures JP. Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. *J Rheumatol* 1991;18:1323–7.
 169. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis: a thirty-six-week, double-blind trial. *Arthritis Rheum* 1990;33:330–8.
 170. Szanto E. Low-dose methotrexate treatment of rheumatoid arthritis: long-term observation of efficacy and safety. *Clin Rheumatol* 1989;8:323–30.
 171. Tishler M, Caspi D, Rosenbach TO, Fishel B, Wigler I, Segal R, et al. Methotrexate in rheumatoid arthritis: a prospective study in Israeli patients with immunogenetic correlations. *Ann Rheum Dis* 1988;47:654–9.
 172. Leonard PA, Clegg DO, Carson CC, Cannon GW, Egger MJ, Ward JR. Low dose pulse methotrexate in rheumatoid arthritis: an 8-year experience with hepatotoxicity. *Clin Rheumatol* 1987;6:575–82.
 173. Weinstein A, Marlowe S, Korn J, Farouhar F. Low-dose methotrexate treatment of rheumatoid arthritis: long-term observations. *Am J Med* 1985;79:331–7.
 174. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study. *Arthritis Rheum* 1994;37:1492–8.
 175. McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. *J Rheumatol* 1993;20:1850–6.
 176. Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. *Rheumatol Int* 1996;15:195–200.
 177. Andersen LS, Hansen EL, Knudsen JB, Wester JU, Hansen GV, Hansen TM. Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: relation to withdrawal and side effects. *J Rheumatol* 1997;24:830–7.
 178. Nisar M, Carlisle L, Amos RS. Methotrexate and sulphasalazine as combination therapy in rheumatoid arthritis. *Br J Rheumatol* 1994;33:651–4.
 179. Gerards AH, Landewe RB, Prins AP, Bruyn GA, Goei The HS, Laan RF, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial [published erratum appears in *Ann Rheum Dis* 2003;62:1126]. *Ann Rheum Dis* 2003;62:291–6.
 180. Peltomaa R, Paimela L, Helve T, Leirisalo-Repo M. Comparison of intramuscular gold and sulphasalazine in the treatment of early rheumatoid arthritis: a one year prospective study. *Scand J Rheumatol* 1995;24:330–5.
 181. Jones E, Jones JV, Woodbury JF. Response to sulfasalazine in rheumatoid arthritis: life table analysis of a 5-year followup. *J Rheumatol* 1991;18:195–8.
 182. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. *Hepatology* 1984;4:430–5.
 183. Child CG, Turcotte JG. Surgery and portal hypertension. *Major Probl Clin Surg* 1964;1:1–85.
 184. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973;60:646–9.
 185. Giner Galvan V, Oltra MR, Rueda D, Esteban MJ, Redon J. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. *Clin Rheumatol* 2007;26:971–2.
 186. Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. *Gut* 1994;35:569–70.
 187. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis [published erratum appears in *J Immunol* 1993;150:2563]. *J Immunol* 1992;149:3339–44.
 188. Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. *Liver Int* 2006;26:1029–39.
 189. Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, Ishikawa T, et al. Lack of tumor necrosis factor α induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. *J Virol* 2003;77:2469–76.
 190. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor- α therapy: guidelines for clinical approach. *J Gastroenterol Hepatol* 2006;21:1366–71.
 191. Nagashima M, Shu G, Yamamoto K, Yamahatsu S, Yoshino S. The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis: epidemiology of DMARDs treatment in Japan. *Clin Exp Rheumatol* 2005;23:27–35.
 192. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. *J Rheumatol* 1989;16:313–20.
 193. Bermas BL. Use of immunosuppressive drugs in pregnancy and lactation. 2007. URL: http://patients.uptodate.com/topic.asp?file=tx_rheum/9876.
 194. Ostensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. *Arthritis Res Ther* 2006;8:209.
 195. Ambrosius Christensen L, Rasmussen SN, Hansen SH, Bondesen S, Hvidberg EF. Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to

- 5-aminosalicylic acid. *Acta Obstet Gynecol Scand* 1987;66:433–5.
196. Hunt MJ, Salisbury EL, Grace J, Armati R. Black breast milk due to minocycline therapy. *Br J Dermatol* 1996;134:943–4.
197. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. *Am J Obstet Gynecol* 1972;112:978–80.
198. Ostensen M, Motta M. Therapy insight: the use of antirheumatic drugs during nursing. *Nat Clin Pract Rheumatol* 2007;3:400–6.
199. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. *J Rheumatol* 2003;30:241–6.
200. Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. *Dig Dis Sci* 2006;51:2045–7.
201. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. *Am J Gastroenterol* 2004;99:2385–92.
202. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. *Aliment Pharmacol Ther* 2005;21:733–8.
203. Ojeda-Urbe M, Gilliot C, Jung G, Drenou B, Brunot A. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. *J Perinatol* 2006;26:252–5.
204. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)- α therapy. *Rheumatology (Oxford)* 2007;46:695–8.
205. Sills ES, Perloe M, Tucker MJ, Kaplan CR, Palermo GD. Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis. *Am J Reprod Immunol* 2001;46:366–8.
206. Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. *Semin Arthritis Rheum* 2005;35:112–21.
207. Van Deventer SJ. Anti-tumour necrosis factor therapy in Crohn's disease: where are we now? *Gut* 2002;51:362–3.
208. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy [letter]. *Gut* 2005;54:890.
209. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor- α inhibition therapy. *Foot Ankle Int* 2004;25:331–5.
210. Den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. *J Rheumatol* 2007;34:689–95.
211. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. *Arthritis Rheum* 2006;55:333–7.
212. Shergy WJ, Phillips RM, Hunte RE, Hernandez J. Infliximab and its impact on surgical outcomes in patients with rheumatoid arthritis [abstract]. *Ann Rheum Dis* 2005;64 Suppl III:465.
213. Bibbo C, Anderson RB, Davis WH, Norton J. The influence of rheumatoid chemotherapy, age, and presence of rheumatoid nodules on postoperative complications in rheumatoid foot and ankle surgery: analysis of 725 procedures in 104 patients [published erratum appears in *Foot Ankle Int* 2003;24:118]. *Foot Ankle Int* 2003;24:40–4.
214. Bridges SL Jr, Lopez-Mendez A, Han KH, Tracy IC, Alarcon GS. Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis? *J Rheumatol* 1991;18:984–8.
215. Carpenter MT, West SG, Vogelgesang SA, Casey Jones DE. Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. *Orthopedics* 1996;19:207–10.
216. Escalante A, Beardmore TD. Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis. *J Rheumatol* 1995;22:1844–51.
217. Fuerst M, Mohl H, Baumgartel K, Ruther W. Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. *Rheumatol Int* 2006;26:1138–42.
218. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. *Ann Rheum Dis* 2001;60:214–7.
219. Jain A, Witbreuk M, Ball C, Nanchahal J. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. *J Hand Surg [Am]* 2002;27:449–55.
220. Kasdan ML, June L. Postoperative results of rheumatoid arthritis patients on methotrexate at the time of reconstructive surgery of the hand. *Orthopedics* 1993;16:1233–5.
221. Perhala RS, Wilke WS, Clough JD, Segal AM. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. *Arthritis Rheum* 1991;34:146–52.
222. Pieringer H, Stuby U, Biesenbach G. Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment? *Semin Arthritis Rheum* 2007;36:278–86.
223. Sany J, Anaya JM, Canovas F, Combe B, Jorgensen C, Saker S, et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. *J Rheumatol* 1993;20:1129–32.
224. Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S. Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. *J Clin Rheumatol* 2003;9:115–8.
225. Bresnihan B. Clinical experience with interleukin-1 receptor antagonist in rheumatoid arthritis. *J Clin Rheumatol* 2001;7:S12–6.
226. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. *Arthritis Rheum* 1996;39:723–31.
227. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of DMARDs in women with RA of childbearing age: a survey of practice patterns and pregnancy outcomes [letter]. *J Rheumatol* 2004;31:401–2.
228. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. *Arch Intern Med* 2000;160:610–9.
229. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. *Clin Drug Investig* 2006;26:55–62.
230. Van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers JR. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. *Drug Saf* 2004;27:345–52.
231. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. *Ann Intern Med* 2004;141:715–7.
232. Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: implications for vaccination programs. *J Infect Dis* 2002;185:713–9.
233. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. *Clin Infect Dis* 2002;34:147–53.
234. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis:

- the effect of disease modifying drugs, including TNF α blockers. *Ann Rheum Dis* 2006;65:191-4.
235. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2006;45:106-11.
 236. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK, the Advisory Committee on Immunization Practices (ACIP), and the Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published errata appear in *MMWR Morb Mortal Wkly Rep* 2006;55:1303, *MMWR Morb Mortal Wkly Rep* 2007;56:256, and *Pediatrics* 2007;119:1008]. *MMWR Recomm Rep* 2006;55:1-48.
 237. Centers for Disease Control and Prevention. Recommended adult immunization schedule: United States, October 2005-September 2006. *MMWR Morb Mortal Wkly Rep* 2005;54:Q1-4.
 238. Jeurissen ME, Boerbooms AM, van de Putte LB, Doesburg WH, Lemmens AM. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis: a randomized, double-blind study. *Ann Intern Med* 1991;114:999-1004.
 239. Committee on Rheumatologic Care. Screening for hydroxychloroquine retinopathy. 2006. URL: <http://www.rheumatology.org/publications/position/hydroxyp2.asp?aud=mem>.
 240. Kaine J, Kivitz A, Birbara C, Luo AY. Effect of adalimumab (Humira) on response to influenza virus and pneumococcal vaccines in patients with rheumatoid arthritis (RA) [abstract]. *Ann Rheum Dis* 2006;65 Suppl II:304.
 241. Oren C, Mendelbaum M, Paran D, Ablin J, Litinsky I, Levartovsky D, et al. Vaccination against influenza in rheumatoid arthritis patients: the effect of rituximab on the humoral response [abstract]. *Arthritis Rheum* 2006;54 Suppl 9:S515.
 242. Corbo M, Tay LK, Leon F, Vratsanos GS. A single dose of abatacept does not prevent the development of a positive immune response to tetanus and pneumococcal vaccines [abstract]. *Ann Rheum Dis* 2006;65 Suppl II:184.
 243. Kapetanovic MC, Saxne T, Nilsson J, Pistoro F, Geborek P. Influenza vaccination as a model for testing immune modulation of anti-TNF and methotrexate therapy in rheumatoid arthritis patients [abstract]. *Ann Rheum Dis* 2006;65 Suppl II:184.
 244. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection. United States, 2003. *MMWR Morb Mortal Wkly Rep* 2003;52:735-9.
 245. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a joint statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. *Am J Respir Crit Care Med* 2000;161:S221-47.
 246. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A, the Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, and the Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting *Mycobacterium tuberculosis* infection, United States [published erratum appears in *MMWR Morb Mortal Wkly Rep* 2005;54:1288]. *MMWR Recomm Rep* 2005;54:49-55.
 247. Pai M, Riley LW, Colford JM Jr. Interferon- γ assays in the immunodiagnosis of tuberculosis: a systematic review. *Lancet Infect Dis* 2004;4:761-76.
 248. Mariette X, Salmon D, and the Group RATIO. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. *Ann Rheum Dis* 2003;62:791.
 249. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. Tuberculosis associated with therapy against tumor necrosis factor α . *Arthritis Rheum* 2005;52:2968-74.
 250. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al, for the START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial [published erratum appears in *Arthritis Rheum* 2007;56:1675]. *Arthritis Rheum* 2006;54:1075-86.
 251. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al, on behalf of the BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. *Arthritis Rheum* 2005;52:1766-72.
 252. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing *Mycobacterium tuberculosis* infection and disease in patients due to start anti-TNF- α treatment. *Thorax* 2005;60:800-5.
 253. Fransen J, Stucki G, van Riel PL. Rheumatoid Arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). *Arthritis Rheum* 2003;49 Suppl 9:S214-24.
 254. Fransen J, Hauselmann H, Michel BA, Caravatti M, Stucki G. Responsiveness of the Self-Assessed Rheumatoid Arthritis Disease Activity Index to a flare of disease activity. *Arthritis Rheum* 2001;44:53-60.
 255. Pincus T, Yazici Y, Bergman M. A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10-20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. *Best Pract Res Clin Rheumatol* 2007;21:755-87.